Odyssey Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Odyssey Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-51.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 72% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-24.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 60% of Healthcare companies in United States.
Cash Cushion Ratio
+17%Cash, after subtracting all debt, equals 17% of its market value (net cash).
Higher than 60% of Healthcare companies in United States.
Tangible Assets Ratio
95%Of every $100 the company owns, $95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 70% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Odyssey Therapeutics, Inc. made a loss over the last year. Odyssey Therapeutics, Inc. owes $0.13 for every $1 it owns. Odyssey Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOdyssey Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.24The share price is 2.24 times Odyssey Therapeutics, Inc.'s book value per share, lower than 54% of Healthcare companies in United States.
Market cap
$942 MThe total market value of all of Odyssey Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 63% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$421 MWhat Odyssey Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$8.76Net worth divided by the number of shares. The share price of $19.60 is 2.2 times this, which is the P/B above.
Owes vs Owns
0.13×Odyssey Therapeutics, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Dividend yield
NoneOdyssey Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-33%Revenue fell 33% in the year to Dec 2025.
Profit growth
LossOdyssey Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-4994.9%Odyssey Therapeutics, Inc. lost $4995 for every $100 of revenue.
Interest cover
Not coveredOdyssey Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashOdyssey Therapeutics, Inc. held $154 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Odyssey Therapeutics, Inc.: $942 M ÷ $421 M (30 Jun 2026) = 2.2.
How much does Odyssey Therapeutics, Inc. owe compared with what it owns?
Odyssey Therapeutics, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Does Odyssey Therapeutics, Inc. pay a dividend?
No. Odyssey Therapeutics, Inc. does not currently pay a dividend.
Is Odyssey Therapeutics, Inc.'s revenue growing?
Revenue fell 33% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.